title: Randomised, double blind, multicentre comparison of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment: results of the HANE study. HANE Trial Research Group.
abstract: OBJECTIVE
  To compare the effectiveness and tolerability of hydrochlorothiazide, atenolol, nitrendipine, and enalapril in patients with mild to moderate hypertension.
  
  
  METHODS
  Randomised multicentre trial over 48 weeks with double blind comparison of treatments.
  
  
  METHODS
  48 centres in four countries.
  
  
  METHODS
  868 patients with essential hypertension (diastolic blood pressure 95-120 mm Hg)
  
  
  METHODS
  Initial treatment (step 1) consisted of 12.5 mg hydrochlorothiazide (n = 215), 25 mg atenolol (n = 215), 10 mg nitrendipine (n = 218), or 5 mg enalapril (n = 220) once daily. If diastolic blood pressure was not reduced to < 90 mm Hg within four weeks, doses were increased to 25 mg, 50 mg, 20 mg, 10 mg, respectively, once daily (step 2) and after two more weeks to twice daily (step 3). The eight week titration phase was followed by an additional 40 weeks for patients who had reached the target diastolic pressure.
  
  
  METHODS
  Blood pressure by means of an automatic device with repeated measurements.
  
  
  RESULTS
  After eight weeks the response rate for atenolol (63.7%) was significantly higher than for enalapril (50.0%), hydrochlorothiazide (44.7%), or nitrendipine (44.5%). After one year atenolol was still more effective (48.0%) than hydrochlorothiazide (35.4%) and nitrendipine (32.9%), but not significantly better than enalapril (42.7%). The treatment related dropout rate was higher (P < 0.001) in the nitrendipine group (n = 28).
  
  
  CONCLUSIONS
  There is no evidence of superiority for antihypertensive effectiveness or tolerability of the "new" classes of antihypertensives (calcium channel blockers and angiotensin converting enzyme inhibitors). As these drugs are now widely used as treatment of first choice, our results further emphasise the need for studies confirming that they also reduce morbidity and mortality, as has been shown for diuretics and beta blockers.
authors.affiliation: Zentrum für Innere Medizin, Universitätsklinikum Essen, Germany.
authors.forename: T
authors.initials: T
authors.lastname: Philipp
authors.forename: M
authors.initials: M
authors.lastname: Anlauf
authors.forename: A
authors.initials: A
authors.lastname: Distler
authors.forename: H
authors.initials: H
authors.lastname: Holzgreve
authors.forename: J
authors.initials: J
authors.lastname: Michaelis
authors.forename: S
authors.initials: S
authors.lastname: Wellek
mesh_terms: D000328:Adult; D000368:Aged; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001262:Atenolol / Q000009:adverse effects / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D004311:Double-Blind Method; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects / Q000627:therapeutic use; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009568:Nitrendipine / Q000009:adverse effects / Q000627:therapeutic use; D012737:Sex Factors; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D006852:Hydrochlorothiazide; D001262:Atenolol; D004656:Enalapril; D009568:Nitrendipine